Burzynski Research Institute

Burzynski Research Institute (BRI), a biopharmaceutical company committed to developing treatment for cancer based on genomic and epigenomic principles. Research and developmental efforts are focused on cancer treatment with four pipeline drugs—antineoplastons (ANP) in 1 Phase III clinical trial and 14 Phase II clinical trials, some of which are ready to enter Phase III.

The ultimate goal of the BRI is to discover, develop, and obtain the FDA's marketing approval of ANP for the treatment of currently incurable types of cancer with emphasis on malignant brain tumors in adults and children.

BRI was incorporated under the laws of the State of Delaware in 1984 in order to engage in the research, production, marketing, promotion and sale of certain medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives and organic acids which are known under the trade name antineoplastons.

Please visit the Burzynski Research Institute website for more information.